Loading
Tenalisib is an oral pi3k inhibitor from Rhizen Pharmaceuticals SA, in registered phase 2 trials for triple-negative breast cancer.
Tenalisib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Rhizen Pharmaceuticals SA, in triple-negative breast cancer. A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling.
1.Tenalisib slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Tenalisib" OR ABSTRACT:"Tenalisib" OR TITLE:"RP6530" OR ABSTRACT:"RP6530") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tenalisib, not a curated reading list.
Shares Triple-negative breast cancer (TNBC) and the tags pipeline, registry-only.
Shares Triple-negative breast cancer (TNBC) and the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.